BiotechTube

Pemigatinib

Phase 2Completed
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

MPN (Myeloproliferative Neoplasms)

Conditions

MPN (Myeloproliferative Neoplasms)

Trial Timeline

Apr 25, 2017 → Oct 30, 2024

NCT ID
NCT03011372

About Pemigatinib

Pemigatinib is a phase 2 stage product being developed by Incyte for MPN (Myeloproliferative Neoplasms). The current trial status is completed. This product is registered under clinical trial identifier NCT03011372. Target conditions include MPN (Myeloproliferative Neoplasms).

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (15)

NCT IDPhaseStatus
NCT03906357Pre-clinicalCompleted
NCT07434843Phase 2Recruiting
NCT06300528Phase 2Recruiting
NCT06906562Phase 2Recruiting
NCT06653777Phase 2Recruiting
NCT05565794Phase 2Terminated
NCT05267106Phase 2Terminated
NCT05253807Phase 2Completed
NCT03914794Phase 2Completed
NCT04294277Phase 2Terminated
NCT04003623Phase 2Terminated
NCT03822117Phase 2Terminated
NCT03235570Phase 1Completed
NCT03011372Phase 2Completed
NCT02924376Phase 2Completed

Competing Products

6 competing products in MPN (Myeloproliferative Neoplasms)

See all competitors
ProductCompanyStageHype Score
RuxolitinibIncytePhase 2
49
Parsaclisib + Parsaclisib + Ruxolitinib + Parsaclisib + ParsaclisibIncytePhase 2
49
Ruxolitinib + Anagrelide + Placebo + PlaceboIncytePhase 2
49
itacitinibIncytePhase 2
49
Ruxolitinib + PlaceboIncytePhase 3
74
Itacitinib + RuxolitinibIncytePhase 2
49

Other Products from Incyte

ruxolitinib creamApproved
82
Itacitinib + Placebo + Prednisone + MethylprednisolonePhase 3
74
Povorcitinib + PlaceboPhase 3
74
Ruxolitinib Cream + Vehicle CreamPhase 3
74
Tacrolimus (Tac) + Methotrexate (MTX) + Ruxolitinib (Rux) + Cyclophosphamide + Mycophenolate mofetil (MMF)Phase 3
74